Anti-Cytokeratin 5 (C-Term, human) Rabbit Monoclonal Antibody (Clone RM226)

Cytokeratin 5 is a type II epithelial intermediate filament protein. It is composed of a central rod containing four alpha-helical domains, which are important for self-assembly, and non-helical head and tail domains at the N- and C-termini, respectively. Cytokeratin 5 is expressed in basal keratinocytes in the epidermis and is an integral component of the epithelial cell cytoskeleton. It dimerizes with the type I epithelial intermediate filament protein cytokeratin 14 via heptad repeats in the central rod domain to form a network of filament bundles throughout the cytoplasm. Cytokeratin 5 interacts with beta-catenin in estrogen receptor-positive breast cancer cells and promotes the reduction of beta-catenin levels at the cell surface in vitro and in a patient-derived xenograft (PDX) mouse model of breast cancer. The expression of cytokeratin 5 in cancer cells predicts poor prognosis in estrogen receptor-positive breast cancer. Mutations in the tail or head domains of cytokeratin 5 induce cytoskeletal abnormalities and keratin aggregation and are associated with epidermolysis bullosa simplex (EBS) while head domain mutations are associated with Dowling-Degos disease. Cayman's Cytokeratin 5 (C-Term, human) Rabbit Monoclonal Antibody (Clone RM226) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.Synonyms: CK-5, Keratin-5, Keratin, Type II Cytoskeletal 5, KRT5. Immunogen: Peptide from the C-terminal region of human cytokeratin 5. Clone Designation: RM226. Formulation: (Request formulation change), 100 µl or 1 ml of protein A-affinity purified monoclonal antibody. Storage Buffer: PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide. Host: Rabbit. Isotype: IgG. Applications: IHC, WB. Cross Reactivity: (+) Cytokeratin 5, (-) Cytokeratin 6.